Stryker announces intention to nominate Jim Davis to board of directors
Portage, MI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Stryker announces intention to nominate Jim Davis to board of directors
Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the company’s board, effective Jan. 1, 2027.
Jim serves as Chairman, CEO and President of Quest Diagnostics. He brings extensive leadership experience across healthcare, medical technology and global operations.
Before joining Quest, Jim served as CEO of InSightec, Inc., a global medical device company. Prior to that, he spent two decades in senior management roles across General Electric’s healthcare and aviation businesses, including five years leading GE’s MRI business. Before GE, Jim led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc.
Jim holds a master’s degree in management from the MIT Sloan School of Management, a master’s degree in science from MIT and a bachelor’s degree in aeronautical engineering from the University of Michigan.
“We are pleased to have Jim as a nominee for our board,” said Kevin Lobo, Chair and CEO, Stryker. “His deep healthcare experience, operational leadership and understanding of medical technology will be a strong addition as we continue to advance Stryker’s strategy and mission.”
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or nick.mead@stryker.com
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600
or kim.montagnino@stryker.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
4 Growth Stocks to Buy While They’re Still Undervalued
United States